News

What’s a SPAC? A Route to Public Markets for Gemini Therapeutics

By Heather Johnson | March 3, 2021

Gemini Therapeutics, a biotech company with a focus on precision medicine for ocular and renal disease, started trading last month on the Nasdaq Global Market…

Read More

Ocular Gene Therapy Takes Next Step Beyond Inherited Retinal Disease

By Rich Kirkner | February 23, 2021

Ten years from now, gene therapy for ocular disease will have made the shift from exclusively targeting inherited retinal diseases with very small populations, such…

Read More

Verana Health and Janssen Enter Real-World Data and Data Science Collaboration

By Steve Lenier | February 16, 2021

Verana Health has entered into a research collaboration with Janssen Research & Development, a unit of Johnson & Johnson, that focuses on curating real-world data…

Read More

With New Clarity of Trial Data, Outlook Therapeutics Stock Rebounds

By Heather Johnson | February 10, 2021

What a difference a few months makes. Outlook Therapeutics’ stock price plunged last August on the heels of top-line results from the NORSE 1 clinical…

Read More

Merge Ahead: Where the Parallel Tracks for Future Innovations in Presbyopia May Meet

By Conni Bergmann Koury | February 2, 2021

Innovations for treating presbyopia are moving on two parallel tracks: accommodative intraocular lenses (IOLs) that are both reversable and exchangeable, and pharmaceutical drops to temporarily…

Read More

Heru Emerges from Stealth Mode to Leverage AI, VR to Test and Treat Visual Field Defects

By Conni Bergmann Koury | January 26, 2021

Heru, an ophthalmology development company creating an artificial intelligence-driven vision diagnostics and augmentation platform, has just emerged from “stealth mode” and made its public debut…

Read More

The Strategy Behind EyeGate’s Acquisition of Panoptes

By Heather Johnson | January 18, 2021

With the acquisition of Vienna-based biotech Panoptes Pharma, Eye Gate Pharmaceuticals has expanded its pipeline of nonsteroidal products targeting ocular inflammation by adding Panoptes’ PP-001,…

Read More

Lessons learned for Conducting Clinical Trials in Challenging Times

By Rich Kirkner | January 12, 2021

Clinical trials on many levels have been disrupted over the past year, and the current surge can cause further disruption as different regions and cities…

Read More
Looking Ahead to 2021, Finding Value in 2020’s Lessons

Looking Ahead to 2021, Finding Value in 2020’s Lessons

By Steve Lenier | January 5, 2021

Robert Kissling, VP, medical affairs for Bausch + Lomb, says forced changes can be the mother of innovation. If so, then 2020 should have sired…

Read More

Novartis Steps Up Digital Strategy for AMD Treatments and Patient Support

By Heather Johnson | December 22, 2020

Novartis is doubling down on its mission to end preventable blindness, which has translated into a host of moves to strengthen its commitment to age-related…

Read More

800-pound Gorilla Doesn’t Deter Investors in Ophthalmology Sector

By Rich Kirkner | December 16, 2020

The coronavirus pandemic became the 800-pound gorilla dragging down the economy this year, but 2020 turned out to be a stellar one for investors in…

Read More

With Hemera Deal, Janssen Continues Building Out Its Retina Portfolio: Glaucoma on the Horizon

By Rich Kirkner | December 8, 2020

By acquiring the rights to Hemera Biosciences’ gene therapy candidate to treat geographic atrophy – the debilitating end-stage form of dry age-related macular degeneration –…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.